Astrazeneca (AZN) EBITDA Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly EBITDA Margin of 3522.08% for Q1 2026, down 191576.0% year-over-year from N/an in Q1 2025, and down 92.4% on a QoQ basis from 46316.67% in Q4 2025.
Astrazeneca (AZN) EBITDA Margin (2009 - 2026) Analysis & Trends
Astrazeneca (AZN) has reported EBITDA Margin for 18 consecutive years, with 3522.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 191576.0% year-over-year to 3522.08%; the TTM figure through Mar 2026 stood at 11395.1% (up 1050203.0% YoY), while the FY2025 annual figure was 22.02%, down 65414.0% from the prior year.
- EBITDA Margin came in at 3522.08% for Q1 2026 at Astrazeneca, down from 46316.67% in the prior quarter.
- The five-year high for EBITDA Margin was 48275.0% in Q2 2024, with the low at 24400.0% in Q2 2022.
- Average EBITDA Margin over 5 years is 9055.59%, with a median of 1084.18% recorded in 2022.
- Across the five-year window, EBITDA Margin sank 2508057 bps in 2022 and jumped 4845479 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 1084.18% in 2022, then slumped by 41 bps to 642.6% in 2023, then plunged by 102 bps to 13.62% in 2024, then soared by 340173 bps to 46316.67% in 2025, then plunged by 92 bps to 3522.08% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 3522.08%, 46316.67%, and 23409.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 18.85% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.85% |
| Dec 31, 2025 | 19.12% |
| Sep 30, 2025 | 17.93% |
| Jun 30, 2025 | 25.78% |
| Mar 31, 2025 | 31.25% |
| Dec 31, 2024 | -0.83% |
| Sep 30, 2024 | 20.53% |
| Jun 30, 2024 | 15.51% |
| Mar 31, 2024 | -3.42% |
| Dec 31, 2023 | 15.72% |
| Sep 30, 2023 | -1.08% |
| Jun 30, 2023 | -3.19% |
| Mar 31, 2023 | 3.58% |
| Dec 31, 2022 | 15.29% |
| Sep 30, 2022 | 6.09% |
| Jun 30, 2022 | -6.89% |
| Mar 31, 2022 | 3.56% |
| Dec 31, 2021 | -3.48% |
| Sep 30, 2021 | -20.34% |
| Jun 30, 2021 | 14.80% |